<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan N Baer, MD, MACR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vidya Sankar, DMD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert I Fox, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H24155376"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sjögren’s disease (SjD) is a chronic multisystem inflammatory disorder characterized by lymphocytic infiltration of the lacrimal and salivary glands and resultant dry eyes and mouth. A variety of other disease manifestations may also be present, including additional issues with sicca, such as dryness of the skin, nasal passages, and vagina; extraglandular involvement; and systemic symptoms, such as fever and malaise. Both local and systemic medical therapies are used in the treatment of the different manifestations of SjD [<a href="#rid1">1-4</a>].</p><p>The treatment of dry mouth, including topical therapy, mechanical/gustatory stimulants, and the use of systemic cholinergic agents and other systemic therapies, along with other therapies for the management of other non-ocular sicca symptoms of SjD, will be reviewed here. Other issues in SjD, including the clinical manifestations, the diagnosis, the treatment of dry eye, and the role of systemic therapy in extraglandular manifestations of SjD, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a> and  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease"</a> and  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a> and  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a> and  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations"</a>.)</p><p class="headingAnchor" id="H4617715"><span class="h1">TREATMENT OF DRY MOUTH</span><span class="headingEndMark"> — </span>Treatment of dry mouth due to salivary gland hypofunction aims to alleviate symptoms and prevent complications such as dental caries, gingivitis, halitosis, salivary gland calculi, dysphagia, and oral candidiasis.</p><p>Various strategies are employed to compensate for the loss of normal salivary functions; these functions include lubricating the mucosa, helping to clear food residue that may lead to dental plaque and bacterial growth, buffering acids that favor demineralization of teeth, and providing antimicrobial effects [<a href="#rid5">5</a>]. Thus, stimulating residual salivary flow, providing lubrication, and treating fungal infection, along with close attention to dental care, are the major aspects of treatment [<a href="#rid5">5-7</a>].</p><p>Our treatment approach is consistent with expert opinion and is supported by the evidence reviewed here [<a href="#rid6">6-9</a>]. Briefly, this approach includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Basic self-care measures to stimulate oral secretions and prevent oral dryness and dental caries, as well as regular preventive dental care. (See <a class="local">'Basic measures for all patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a> in patients who receive insufficient benefit from mechanical stimulation of salivary flow or water or who have maximized water intake (eg, resulting in nocturia). (See <a class="local">'Inadequate benefit from salivary stimulation and water'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of muscarinic agonists (eg, <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> or <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>) in patients with an inadequate response to mechanical stimulation and <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a>. (See <a class="local">'Mechanical and gustatory stimulation of salivary flow'</a> below and <a class="local">'Inadequate response to salivary stimulation and substitutes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specialized interventions by a dentist with expertise in dry mouth dentistry in patients with dental caries or with very low salivary production. (See <a class="local">'Basic dental care and oral hygiene'</a> below and <a class="local">'Dental professional care'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high level of suspicion for oral candidiasis, which is a common complication in patients with Sjögren’s disease (SjD). Such patients may describe symptoms such as burning, mouth pain, or sensitivity and may exhibit apparent resistance to treatment for symptoms of oral dryness. (See <a class="local">'Oral candidiasis'</a> below.)</p><p></p><p class="headingAnchor" id="H24155398"><span class="h2">Basic measures for all patients</span><span class="headingEndMark"> — </span>The following measures should be used in all patients with dry mouth due to SjD, regardless of symptom severity:</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of dryness (see <a class="local">'Prevention of dryness'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Stimulation of secretions (see <a class="local">'Mechanical and gustatory stimulation of salivary flow'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Dental prophylaxis (see <a class="local">'Basic dental care and oral hygiene'</a> below)</p><p></p><p>Prevention and management of potential complications of dry mouth are an important component of patient education. Patients should be instructed regarding signs and symptoms of oral candidiasis, which may mimic or exacerbate dry mouth symptoms and require prompt intervention. Additionally, they should be cautioned regarding the risks of cosmetic dental procedures in the setting of severe salivary hypofunction. (See <a class="local">'Oral candidiasis'</a> below and <a class="local">'Restorative and cosmetic dentistry'</a> below.)</p><p>The published evidence supporting these measures is limited, largely consisting of small trials, case series, and clinical experience [<a href="#rid5">5-8,10,11</a>].</p><p class="headingAnchor" id="H902090"><span class="h3">Prevention of dryness</span><span class="headingEndMark"> — </span>Preventive measures against dry mouth include:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of good hydration by taking regular sips of water, drinking sugar-free liquids, and avoidance of oral irritants (eg, coffee, alcohol, and nicotine).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of oral desiccants (eg, coffee, alcohol, tobacco and cannabis smoke).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of medications that may worsen oral dryness, especially those with anticholinergic side effects. Medications for urinary incontinence and depression have the strongest association with this side effect [<a href="#rid12">12</a>]. Over-the-counter cold and sleep remedies may be overlooked as potential contributors. (See  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy", section on 'Avoidance of medications causing dryness'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of open nasal passages to avoid mouth breathing. (See <a class="local">'Nasal dryness'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of low-humidity environments, such as air-conditioned stores, centrally heated houses, and airplanes; and implementing the use of humidifiers to maintain adequate humidity, particularly at night.</p><p></p><p>Various solutions can be used to replace oral secretions, ranging from water to forms of <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a>. We suggest frequent sips of water because of convenience, cost, and efficacy. Sufficient water is needed to maintain adequate hydration. However, water used for moistening does not have to be swallowed; it can be rinsed around the mouth and then expectorated. Sucking on ice may be preferred by some patients. The addition of a small amount of liquid omega-3 oil to the water (¼ to ½ teaspoon per 16 oz) may enhance the wetting effect [<a href="#rid11">11</a>].</p><p>Although water provides temporary moisture, it does not provide the lubricating properties that are characteristic of the mucin and water mixtures that constitute normal saliva.</p><p>Patients should be advised that sipping water too often may be counter-productive, reducing the mucus film in the mouth and possibly worsening symptoms. In this case, it is better to drink the water in a large bolus (ie, one cup at a time) to maintain adequate hydration. If water consumption is excessive, especially in the evening, nocturia can occur, resulting in sleep disturbance that may worsen fatigue, cognitive difficulties, and pain that some patients experience.</p><p>We advise patients to avoid sipping highly acidic beverages, particularly between meals, since a sustained lowering of intraoral pH may adversely affect dental enamel [<a href="#rid13">13</a>]. Examples of common beverages and their relative acidity include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cola drinks – pH 2.6</p><p class="bulletIndent1"><span class="glyph">●</span>Coffee – pH 5.0</p><p class="bulletIndent1"><span class="glyph">●</span>Tea (herbal) – pH 3.2</p><p class="bulletIndent1"><span class="glyph">●</span>Tea (black) – pH 5.7 to 7.0</p><p class="bulletIndent1"><span class="glyph">●</span>Water from tap – pH 7.0 (but flavored waters are often acidic)</p><p class="bulletIndent1"><span class="glyph">●</span>Energy drinks – Usually acidic</p><p></p><p>The maintenance of a stable neutral pH in the oral cavity is highly important since this serves to decrease dental demineralization. The buffering systems responsible for the human saliva buffering capacity include bicarbonate, phosphate, and protein. Even a minor drop in pH can promote dental caries or can damage the teeth by erosion [<a href="#rid14">14</a>]. The pH and buffering capacity of the parotid saliva of individuals with SjD are much lower than those in healthy individuals.</p><p class="headingAnchor" id="H24155412"><span class="h3">Mechanical and gustatory stimulation of salivary flow</span><span class="headingEndMark"> — </span>All patients with dry mouth should use mechanical and gustatory stimulants, in addition to the basic measures described for prevention of dryness and dental care (see <a class="local">'Prevention of dryness'</a> above and <a class="local">'Basic dental care and oral hygiene'</a> below). Salivary flow may be stimulated in patients with residual salivary function by sucking on sugar-free candies and lozenges and by using sugar-free chewing gums [<a href="#rid5">5,7</a>]. Particular care must be taken not to increase the risk of dental caries by the prolonged use of sugar-containing products and by avoidance of acidic drinks (eg, carbonated beverages and citrus juices). (See <a class="local">'Prevention of dryness'</a> above.)</p><p>The choice of stimulatory agent largely depends upon patient preference. A clear advantage of one product over another has not been rigorously shown, and a variety of products should be tried to determine which is most acceptable and effective in a given patient. Although the use of highly acidic products is usually not advised, drops of lemon juice in a glass of water may be used to stimulate saliva production without dropping the pH sufficiently to damage dental enamel.</p><p>Products identified as "sugarless" should be distinguished from those that are "sugar-free," as items identified in the United States as "sugarless" may contain significant amounts of fructose, thus being potentially cariogenic. These and similar terms may be defined differently based upon regulations regarding food labeling in different countries.</p><p>Examples of salivary stimulants include:</p><p class="bulletIndent1"><span class="glyph">●</span>Sugar-free hard candies or lozenges.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sugar-free chewing gums containing various sweeteners such as aspartame, saccharin, and <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>, which can increase saliva production in patients with residual secretory capacity. Excessive sorbitol can lead to gastrointestinal side effects such as cramps and diarrhea [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Xylitol-containing gum or candy, which may also reduce the cariogenicity of the oral bacterial flora [<a href="#rid5">5</a>]. Xylitol can also cause diarrhea and flatulence if used in excess [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topically applied oral inserts (eg, Xylimelt, Salese lozenges) that adhere to the mucosa [<a href="#rid16">16,17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Citrus-flavored sugarless tablets or oral drops, which may also contain malic acid. This acid, which is normally found in fruits such as apples or pears, stimulates salivary flow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dried fruit slices, such as peaches or nectarines, which stimulate salivary flow.</p><p></p><p>A systematic review of topical therapies for xerostomia found 36 small trials (average size of 44 patients), with a wide range of interventions, comparisons, and outcome measures, and a resultant lack of strong evidence for efficacy of any specific topical therapy [<a href="#rid10">10</a>]. Additionally, most of the products were not tested in patients with SjD. However, some evidence suggested a patient preference for chewing gums, which may increase saliva production in patients with residual secretory capacity, although there was no evidence that gum was more or less effective than use of saliva substitutes. Additionally, chewing gums have the benefit that they enhance the patient's own saliva production so that taste and consistency are not an obstacle. The use of these interventions is also supported by extensive clinical experience.</p><p class="headingAnchor" id="H16911880"><span class="h3">Basic dental care and oral hygiene</span><span class="headingEndMark"> — </span>Particular attention to basic dental care is important for all patients with dry mouth; the development of dental caries is a major problem in such patients, who are especially prone to rapidly progressing root and incisal caries [<a href="#rid5">5,18-20</a>]. To help avoid these complications, we suggest aggressive application of the same general dental hygiene principles as in individuals without dry mouth, including meticulous self-care, frequent visits to the dentist (at least every six months for patients with mild disease), and <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> supplementation  (<a class="graphic graphic_table graphicRef114362" href="/z/d/graphic/114362.html" rel="external">table 1</a>).</p><p>Patients should also avoid eating preprocessed "sticky" foods (caramels, taffy, etc), which may be high in sugar content and hard to remove [<a href="#rid6">6,20</a>]. If they drink a sugar-containing beverage, it is best to do so in one sitting (over several minutes) rather than sipping on it throughout the day; this helps to avoid repeated exposure of the teeth to sugar and a drop in oral pH with each exposure. They should remember to perform oral hygiene (brushing/flossing) after each exposure to sugary substances. If this is difficult to achieve, they should at a minimum rinse their mouth vigorously with water after use.</p><p>We suggest that patients do the following under the supervision of their dentist:</p><p class="bulletIndent1"><span class="glyph">●</span>Use dental hygiene techniques regularly to remove trapped food debris and plaque. These include the use of dental floss and dental appliances such as interdental brushes (for cleaning between teeth) and electric toothbrushes. Use dental floss or another interdental cleaner after each meal. Toothbrushing should be done at least twice daily. We advise patients to carry a toothbrush and toothpaste to use when they will not be at home following meals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use topical <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a>, which is highly effective in reducing caries in dry mouth patients. Topical fluorides are available in many different strengths and formulations. The choice of formulation depends in part upon caries risk stratification and changes as caries susceptibility increases. A caries risk assessment by a dental professional involves weighing multiple factors, including the baseline presence of frank caries, erosions of the enamel without penetration into the dentin, or recent (&lt;3 years) dental restoration; the presence of predisposing factors, such as high oral colony counts of cariogenic bacteria, poor dietary habits, absence of saliva, heavy dental plaque, exposed roots, and orthodontic appliances; and protective factors already in place, such as regular access to fluoridated water and use of fluoride toothpastes, varnishes, or rinses [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">We take the following approach  (<a class="graphic graphic_table graphicRef114362" href="/z/d/graphic/114362.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with symptomatic dry mouth but without clinical signs of dry mouth and without recent caries can be treated with over-the-counter fluoride-containing mouth rinses. Patients should be advised to carefully check the labels as not all mouth rinses contain <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with clinical signs of dry mouth but no new carious lesions and no other risk factors, we advise daily use of 1.1% sodium <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> gel (5000 parts per million [ppm]) once a day (preferably at bedtime) in addition to an over-the-counter toothpaste with fluoride (1000 to 1200 ppm) for their daytime brushing.</p><p></p><p>Topical <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> is also beneficial for patients with dental crowns and veneers, preventing caries formation at the margin of the crown and tooth, an area particularly susceptible to such decay.</p><p class="bulletIndent2"><span class="glyph">•</span>We consider any SjD patient with clinical signs of dry mouth (see <a class="local">'Evaluation of response to therapy'</a> below) and/or salivary hypofunction (eg, whole unstimulated saliva flow &lt;0.1 mL/minute) who has developed new incisal or root caries to be at high risk for further caries and in need of an intensive caries prevention program, including quarterly dental examinations and the use of <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> supplementation (ie, daily use of 1.1% sodium fluoride gel or fluoride gel in dental trays and professionally applied fluoride varnishes every three to six months). The patient's dentist should determine if fluoride gel in a custom-fitted tray once daily (1.1% neutral sodium fluoride) is indicated [<a href="#rid5">5,6,22</a>]. These treatments should be coupled with the professional application of a fluoride varnish every three to six months [<a href="#rid6">6</a>]. (See <a class="local">'Dental professional care'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Toothpastes containing 5000 ppm <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> have been shown to be more effective for promoting remineralization and/or inhibiting demineralization than over-the-counter fluoride toothpastes (containing 1000 to 1200 ppm fluoride), particularly in children [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of toothpastes specifically designed for dry mouth if indicated based on an assessment by the patient's dentist. Factors considered in this assessment include the rate of development of caries, the patient's carbohydrate exposure, and the degree of salivary hypofunction. Lack of lubrication in most over-the-counter toothpastes may contribute to irritation to the tongue and cheeks. Dry mouth toothpastes lack detergents, such as sodium lauryl sulfate, which is the foaming agent in most toothpastes and which can irritate the mucosa; however, they do not contain prescription-strength concentrations of <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> [<a href="#rid24">24</a>]. Additionally, while infrequent, we caution patients that some of the prescription-strength fluoride-containing toothpastes may lead to brown discoloration of the teeth, particularly in younger patients [<a href="#rid25">25</a>].</p><p></p><p>The use of topical <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> is supported by strong recommendations of a 2016 guidelines panel of experts on SjD [<a href="#rid8">8</a>]. Most of the evidence in the panel's systematic literature review was from trials involving patients with dry mouth due to radiotherapy for head and neck cancer but also included more limited evidence from several other conditions and one trial that included patients with SjD but lacked a placebo control [<a href="#rid8">8,26</a>]. Since the publication of these 2016 guidelines, the results of a 24-month, randomized trial of quarterly applications of fluoride varnish in 78 SjD patients were published [<a href="#rid27">27</a>]. The fluoride-treated patients had 33 percent less coronal dentin caries compared with placebo, but this difference did not reach statistical significance.</p><p class="headingAnchor" id="H3261393147"><span class="h3">Evaluation of response to therapy</span><span class="headingEndMark"> — </span>The response to therapy may be evaluated by ongoing assessment for common clinical signs of dry mouth [<a href="#rid6">6,28</a>]. In addition to patient-reported dryness, these include:</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty with swallowing or speech due to dryness</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of a pool of saliva on the floor of the mouth</p><p class="bulletIndent1"><span class="glyph">●</span>"Lipstick sign" (spreading of the patient's lipstick onto teeth)</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal adherence (ie, "sticking") of a gloved finger, dental mirror, or wooden tongue depressor to the mucosa</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent occurrence of erythematous oral candidiasis</p><p class="bulletIndent1"><span class="glyph">●</span>Burning mouth symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Atrophic glossitis (or lack of papilla) on the tongue</p><p class="bulletIndent1"><span class="glyph">●</span>Atypical dental caries at the gingival margin and/or incisal regions</p><p></p><p class="headingAnchor" id="H16911567"><span class="h2">Insufficient response to basic measures</span><span class="headingEndMark"> — </span>In patients who do not respond adequately to the basic measures described above and who continue to have signs or symptoms of dry mouth (see <a class="local">'Evaluation of response to therapy'</a> above), further measures may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Saliva substitutes ("<a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a>") (see <a class="local">'Inadequate benefit from salivary stimulation and water'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscarinic agonists, including <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> and <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> (see <a class="local">'Inadequate response to salivary stimulation and substitutes'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic antiinflammatory and immunosuppressive medications, such as <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, for which the evidence for benefit is weak [<a href="#rid29">29</a>] (see <a class="local">'Systemic antiinflammatory and immunosuppressive therapy'</a> below)</p><p></p><p class="headingAnchor" id="H1388608110"><span class="h3">Inadequate benefit from salivary stimulation and water</span></p><p class="headingAnchor" id="H1549641862"><span class="h4">Artificial saliva: Role, selection, and use</span><span class="headingEndMark"> — </span>We suggest the use of <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a> in patients who do not receive sufficient symptomatic benefit from mechanical stimulation, topical stimulants of salivary flow, and water, or who have excessive water intake (eg, resulting in nocturia). A number of artificial saliva preparations that provide more viscosity and lubrication than water are available, generally without prescription. Formulations include sprays, liquid rinses, and gels. These compounds typically contain a unique mix of multiple components in each preparation, such as <a class="drug drug_general" data-topicid="8844" href="/z/d/drug information/8844.html" rel="external">carboxymethylcellulose</a>, polyethylene glycol, <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>, and electrolytes [<a href="#rid7">7,10</a>]. A product containing animal mucin (AS Saliva Orthana) is available in some countries, but not the United States, and may be superior to saliva substitutes with carboxymethylcellulose and hydroxyethyl cellulose in terms of symptom relief [<a href="#rid30">30,31</a>].</p><p>Individual preferences and degree of improvement can differ between patients and between products; therefore, several different products should be tried if a particular substitute is not acceptable due to viscosity, texture, flavor, and other characteristics [<a href="#rid32">32</a>]. The product should be applied to the inner lips, buccal mucosa, tongue, and hard palate. We advise patients to mix and match a variety of these agents in their daily or nightly schedule. For example, a patient may use a mouth spray before speaking to a group, an oral solution before eating to help with dysphagia, and an oral gel before bedtime. Sprays may be more difficult to use for patients with arthritis.</p><p>Saliva substitutes may be most useful during telephone conversations, during social and workplace interactions, and in patients with dentures. If patients eat, drink, or maintain a high degree of salivary flow, these agents will be washed away rapidly and patients will have to reapply the agents frequently. Patients should be informed of the normal diurnal variation in saliva flow, which decreases and has altered composition at night; therefore, saliva substitutes may be most useful before sleep and after waking at night with dry mouth symptoms [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2212071087"><span class="h4">Efficacy of artificial saliva</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a> preparations is supported by several randomized trials and by additional studies that show benefit compared with placebo in relieving symptoms of dry mouth, including burning mouth and tongue, and difficulties with chewing and swallowing [<a href="#rid10">10,32,34-37</a>]. They have not been shown in randomized trials to improve salivary flow, although observations in one open-label study suggested improvement both in symptoms of dryness and in salivary flow with the use of an oral spray containing hydroxymethylcellulose [<a href="#rid10">10,37</a>].</p><p class="headingAnchor" id="H899135"><span class="h3">Inadequate response to salivary stimulation and substitutes</span></p><p class="headingAnchor" id="H902366"><span class="h4">Indications for sialagogues</span><span class="headingEndMark"> — </span>We suggest the use of a muscarinic agonist such as <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> or <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> in patients with salivary hypofunction and xerostomia who do not achieve sufficient salivary secretion or symptomatic relief with topical stimulants or saliva substitute.</p><p>The benefits of <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> and <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> have been shown in several randomized trials of each drug; these include increased salivary flow and improvement in symptoms of dry mouth in comparison with placebo [<a href="#rid38">38-46</a>]. However, pilocarpine and cevimeline have not been compared directly with each other in patients with SjD. (See <a class="local">'Pilocarpine efficacy'</a> below and <a class="local">'Cevimeline efficacy'</a> below.)</p><p>These agents are most useful early in the course of SjD, while the patient still has baseline saliva and greater residual excretory capacity upon stimulation [<a href="#rid40">40,41,47-51</a>]. For SjD patients with residual salivary gland function, it is hoped that stimulation of saliva flow with a secretagogue may aid in preventing long-term oral complications.</p><p class="headingAnchor" id="H899651"><span class="h5">Choice of sialagogue</span><span class="headingEndMark"> — </span>The choice between <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> and <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>, which appear equally efficacious compared with placebo, is largely determined by individual factors; these include cost to the patient, individual clinical response, convenience, and regulatory or insurance limitations on drug availability. The following factors may differentiate the drugs:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">Cevimeline</a>, which has a longer half-life and receptor occupancy time than <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a>, is better tolerated by some patients and usually requires dosing only three, rather than four, times daily [<a href="#rid40">40,41,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">Cevimeline</a> may result in less diaphoresis or flushing than <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> but causes gastrointestinal side effects (eg, nausea, diarrhea) more often [<a href="#rid39">39,41-43</a>]. In a retrospective chart review of 110 patients in an oral medicine clinic, the use of pilocarpine was associated with a higher proportion of adverse events compared with cevimeline, and the adherence rate was higher with cevimeline [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients using <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a>, generally dosed four times daily, typically experience a brief spurt of saliva due to the relatively short serum half-life of this drug [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some formularies require an initial trial of <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a>, which has been available longer, before approving use of <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>, and patients who have not responded to or who have not tolerated pilocarpine may benefit from cevimeline, as shown in trials of cevimeline including patients previously treated with pilocarpine.</p><p></p><p class="headingAnchor" id="H1694955422"><span class="h5">Sialagogue dose</span><span class="headingEndMark"> — </span>The usual dose of <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> is 5 mg by mouth, up to four times daily, and the usual dose of <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> is 30 mg by mouth, up to three times daily taken approximately a half-hour before meals to allow time for the medication to enhance saliva flow for the meal. The dose of pilocarpine or cevimeline should be increased gradually when initiating therapy, starting with one dose daily for a week, which helps to prevent a sudden onset of sweating. Taking the medication with food may alleviate the side effects of dyspepsia and gastric bloating (although this may reduce drug absorption). We suggest a trial of at least three months' duration if the medication is tolerated since the response is frequently delayed.</p><p>An increase in <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> dose from 5 to 7.5 mg every six hours has been effective in some patients who have not responded to the usual dose. In some patients with unacceptable levels of side effects at the full dose, a reduced dose of 2.5 to 3.75 mg three times daily or 5 mg twice daily may still provide benefit [<a href="#rid5">5,45</a>].</p><p><a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">Cevimeline</a> can be taken in a fourth dose at bedtime if needed for nocturnal dryness. Use of lower doses in patients with poor tolerance of the full dose has been reported [<a href="#rid5">5</a>]. A lower dose is prepared by dissolving the desired fraction of a 30 mg capsule's contents in water. The desired fraction can be taken to achieve the desired reduced dose, or the solution can be used in a "rinse-and-spit" regimen to minimize systemic absorption [<a href="#rid5">5,11</a>].</p><p><a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">Pilocarpine</a> oral rinse has been shown to increase salivary flow and relieve dry mouth symptoms in a small study of 19 older adult patients [<a href="#rid54">54</a>]. Systemic side effects were less prevalent than in a clinical trial of oral pilocarpine tablets (5 mg three times daily). It is compounded by dissolving three 5 mg tablets in 150 mL of water. Patients held the rinse in their mouth for two minutes before spitting it out and were allowed to use up to 150 mL of the rinse per day. Similarly, the application of topical ocular pilocarpine drops to the oral cavity (2 to 3 drops of a 4% ocular pilocarpine solution is equivalent to 4 to 6 mg) may facilitate dose titration in an effort to avoid the systemic side effects of oral pilocarpine tablets [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H900232"><span class="h5">Pilocarpine efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">Pilocarpine</a>, a muscarinic agonist that stimulates all muscarinic receptors (M1, M2, and M3), can increase aqueous secretions in patients with residual salivary gland function [<a href="#rid42">42-45,56</a>]. In addition to effects upon xerostomia, pilocarpine may improve symptoms of ocular dryness, although without any objective change in tear production [<a href="#rid45">45</a>]. Improvement in symptoms of nasal, vaginal, and skin dryness has also been reported [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a>.)</p><p>In the largest randomized trial that demonstrated the benefit of <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a>, 357 patients were randomly assigned to receive either pilocarpine (5 or 2.5 mg every six hours) or placebo for 12 weeks [<a href="#rid42">42</a>]. A greater proportion of patients receiving pilocarpine (5 mg), compared with those who received placebo, experienced improvement in global assessments of symptoms of both dry mouth and dry eye (61 versus 31 percent and 42 versus 26 percent, respectively). There was no difference in benefit found between pilocarpine 2.5 mg every six hours and placebo, and the overall withdrawal rate did not differ between the three groups (6 to 7 percent).</p><p>No published studies have examined the long-term efficacy of <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> as a sialogogue in patients with SjD. In a prospective cohort study using national health insurance databases in Taiwan, the use of pilocarpine in 1014 new-onset SjD patients was not associated with a reduction in caries when compared with 2028 SjD patients not using pilocarpine [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H900463"><span class="h5">Cevimeline efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">Cevimeline</a>, an effective sialagogue, is a derivative of acetylcholine with a higher affinity for muscarinic M1 and M3 receptors on the lacrimal and salivary epithelium than for receptors on cardiac tissue [<a href="#rid47">47</a>]. In randomized trials, cevimeline increases salivary flow and patient "oral quality of life" compared with placebo [<a href="#rid39">39,41,46,51,58,59</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> was illustrated in a trial that randomly assigned 197 patients with either primary or secondary SjD to cevimeline or placebo [<a href="#rid39">39</a>]. At 12 weeks, the patients' global assessments of dryness were improved more often by cevimeline 30 mg three times daily than by doses of 15 mg three times daily or by placebo (66 versus 32 and 36 percent, respectively). Patients reported improvement in dry mouth symptoms more often with cevimeline (30 or 15 mg) than with placebo (66 and 45 versus 37 percent, respectively); salivary flow rate was increased in patients on the 30 mg dose compared with placebo but not with the 15 mg dose. In addition, patients reported improvement in dry eye symptoms more often with cevimeline (30 or 15 mg) than with placebo (39 and 31 versus 24 percent, respectively); lacrimal flow was greater with the higher dose of cevimeline than with the lower dose and with either dose of active drug compared with placebo.</p><p>Drugs that inhibit cytochrome CYP2D6 and CYP3A3 also inhibit the metabolism of <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>. Individuals who are known to be deficient in these cytochrome isoenzymes should use cevimeline with caution. More detailed information on drug interactions and a list of medications in each group are available using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p class="headingAnchor" id="H899658"><span class="h5">Adverse effects and precautions</span><span class="headingEndMark"> — </span>The use of these medications (<a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> and <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>) may be limited by poor tolerance, largely due to cholinergic side effects including undesirable levels of increased or excessive sweating, increased urinary frequency, flushing, chills, rhinitis, nausea, and diarrhea [<a href="#rid38">38,39,42-44</a>]. They are contraindicated in patients with uncontrolled asthma and obstructive pulmonary disease. Other infrequent adverse effects of either medication include bradycardia and hypotension [<a href="#rid60">60</a>]. They should be thus used with caution in patients with cardiovascular disease and in those taking beta blockers.</p><p>Patients using these medications should be cautioned about driving at night or performing hazardous activities in reduced lighting because of the very uncommon adverse effects of decreased visual acuity (particularly at night and in patients with central lens changes) and impaired depth perception.</p><p>Some patients do not respond sufficiently enough to the muscarinic agonists to justify continued use, especially when cholinergic side effects are present.</p><p class="headingAnchor" id="H900579"><span class="h4">Inadequate response to sialagogues</span><span class="headingEndMark"> — </span>In patients with an inadequate response to sialagogues, the degree of adherence to the treatment regimen, particularly with dosing four times daily, should be ascertained. Some patients may tolerate a fourth daily dose of <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> or an increase in the dose of <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> if needed. Patients should be instructed to begin with once daily dosing and gradually increase the number of doses if they are able to tolerate the adverse effects (see <a class="local">'Adverse effects and precautions'</a> above). They should also be advised that it may take several weeks to months before they experience a beneficial response so they should not give up too soon. Patients who maintain sufficient saliva flow during meals but find their oral dryness most problematic between meals may try taking the sialagogue 30 minutes after meals instead of prior to meals.</p><p class="headingAnchor" id="H316655"><span class="h3">Systemic antiinflammatory and immunosuppressive therapy</span><span class="headingEndMark"> — </span>We generally do not use systemic antiinflammatory or immunosuppressive therapies for the treatment of sicca symptoms alone, such as dry eye and mouth, although some of these agents have beneficial effects in patients with systemic and extraglandular disease, and a few have shown some efficacy for sicca symptoms, including dry mouth, when used in patients with systemic disease [<a href="#rid61">61,62</a>].</p><p>The use of these agents in patients with systemic and extraglandular manifestations of SjD and the evidence describing their efficacy and safety in SjD are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Therapeutic rationale and evidence overview'</a> and  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Efficacy of specific therapeutic agents'</a>.)</p><p class="headingAnchor" id="H319580"><span class="h3">Investigational and other approaches</span><span class="headingEndMark"> — </span>Several other medications and interventions have been evaluated for use for xerostomia in SjD or in other conditions, but they have significant disadvantages compared with available therapies or have not been adequately studied to justify routine clinical use for patients with SjD. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Several devices (eg, Salitron, Saliwell) that utilize electrical stimulation to increase saliva production have been approved by the US Food and Drug Administration (FDA). These are designed as mouthpieces, handheld stimulators, or dental implants [<a href="#rid63">63</a>]. These may be a therapeutic option for patients who develop intolerable side effects from systemic sialogogues [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acupuncture, which has shown mixed results in a small number of trials for xerostomia resulting from radiation therapy for cancer and which has also been studied in patients with SjD with uncertain benefit [<a href="#rid65">65-71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous delivery of water to the mouth with a micropump and ultrafine tubing (eg, Voutia system).</p><p></p><p class="headingAnchor" id="H319080"><span class="h2">Dental professional care</span></p><p class="headingAnchor" id="H3554861794"><span class="h3">Preventive care and treatment</span><span class="headingEndMark"> — </span>Treatment administered by a dental professional is required for patients with SjD. At a minimum, patients should receive annual dental examinations with twice-yearly dental cleanings in addition to basic dental care (see <a class="local">'Basic dental care and oral hygiene'</a> above). More frequent visits may be necessary depending upon the severity of oral involvement, even in patients who floss and brush regularly with toothpaste containing <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> [<a href="#rid14">14</a>]. Whenever possible, we suggest that patients be seen by a dentist familiar with the care of patients with SjD.</p><p>An alternative resource is those dentists with expertise in dry mouth who may be working collaboratively with radiation oncologists to care for patients with head and neck malignancies; such patients may experience severe sicca symptoms due to radiotherapy.</p><p>Professional dental care includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent cleanings and use of minimally invasive dental techniques to treat caries and other lesions early and to prevent the need for restorative care [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guidance regarding home self-care and oral hygiene, as well as prescription <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> or calcium phosphate preparations when indicated. There are several different topical fluoride preparations available, including toothpastes, gels, mouthwashes, and varnishes. Varnishes need to be applied in the dental office while more potent pastes and gels (eg, PreviDent 5000, Pro-DenRx) require prescriptions. (See <a class="local">'Basic dental care and oral hygiene'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> varnishes after each professional cleaning or topical fluoride gel or foam application (brushed onto tooth surfaces or applied to fluoride delivery trays for more intensive treatment) [<a href="#rid8">8,22</a>]. In most cases, the gels and foams contain either 1.23% acidulated phosphate fluoride or 2% sodium fluoride. Fluoride gel/foam delivery in trays has the advantage of a lengthened contact time with the tooth surface. The varnishes offer ease of application and longer adhesion time to the tooth surface, resulting in a decreased caries rate.</p><p></p><p>Non-fluoride remineralization techniques may benefit some patients. As an example, the remineralization process may be facilitated by the provision of calcium phosphate ions through toothpaste (eg, MI paste, Tom's Rapid Relief Sensitive toothpaste), specialized chewing gums (eg, BasicBites), or oral solutions (eg, Caphosol, NeutraSal, SalivaMAX). Supersaturated calcium phosphate rinses are being marketed to promote remineralization of the teeth and relieve symptoms of xerostomia. A candy containing arginine, bicarbonate, and <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>, designed to neutralize acids in dental plaque and promote tooth mineralization, has been shown to inhibit the development of dental caries in children and is being marketed for dry mouth patients [<a href="#rid72">72</a>]. No long-term clinical trials have been done to test the effectiveness of these agents [<a href="#rid18">18,26,73</a>]. Although there are limited data to support the efficacy of such non-fluoride remineralizing agents for caries prevention in SjD, an expert panel has suggested their use in this disease [<a href="#rid8">8</a>].</p><p>Oral antibacterial interventions are sometimes prescribed. Several approaches may reduce oral bacterial flora, including the use of <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> (CHX), a topical antimicrobial agent, and products containing baking soda, bicarbonate, or xylitol [<a href="#rid5">5,74</a>]. Evidence gathered from three systematic reviews supported the value of CHX (swish for 30 seconds and spit twice daily) and mouthwashes containing essential oils in reducing plaque and gingival inflammation [<a href="#rid75">75</a>]. CHX should be used after brushing and flossing since it may stain dental plaque and food residue. There may be a beneficial effect of CHX in preventing root caries, but the evidence is weak [<a href="#rid8">8,76</a>].</p><p>Polyol sweeteners such as xylitol and <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>, which are not fermentable by acid-producing bacteria, are of low cariogenic potential or are noncariogenic; they may prevent or limit demineralization and may promote the remineralization process [<a href="#rid77">77-81</a>]. Xylitol may be a useful adjunct to other anticaries treatments but should not be considered as a substitute for <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> or other well-established interventions [<a href="#rid5">5,77</a>].</p><p>Given the importance of <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> in the prevention of dental caries, patients at high risk of caries should undergo professional application of fluoride varnish every three to six months, in addition to self-administration of fluoride gels and mouth rinses (including gels applied at home in custom-fitted trays) [<a href="#rid8">8,22</a>] (see <a class="local">'Basic dental care and oral hygiene'</a> above). Patients living in homes or areas without fluoridated water are at particular risk. The increasing use of non-fluoridated bottled water in place of fluoridated tap water has also decreased fluoride exposure for some patients. Topical fluoride promotes remineralization of teeth by the development of a crystalline protective veneer at the site of demineralization and by the inhibition of bacterial metabolism and acid production.</p><p class="headingAnchor" id="H24155844"><span class="h3">Restorative and cosmetic dentistry</span><span class="headingEndMark"> — </span>Patients with SjD may be at greater risk of poor outcomes or adverse effects with certain common procedures used for restorative or cosmetic dental care, including the use of dentures, implants, and brightening products.</p><p class="headingAnchor" id="H17175646"><span class="h4">Dentures and implants</span><span class="headingEndMark"> — </span>Patients with SjD may have more difficulty wearing dentures because of the decreased moisture in the mouth and inability to create an adequate suction/seal between the denture and the roof of the mouth. No adequately controlled clinical trials have addressed this question. In general, dentures cannot replicate the efficiency and comfort of natural teeth.</p><p>There are limited data regarding the ability of patients with SjD to tolerate implants [<a href="#rid82">82,83</a>]. However, it appears that adequate bone height and bone density are keys to the success and longevity of dental implants, as they are in individuals without dry mouth [<a href="#rid84">84</a>]. Favorable outcomes are reported in some series, but long-term follow-up data are very limited [<a href="#rid85">85,86</a>]. Decisions regarding use of implants in a patient with SjD should be made on an individual basis, and the limited evidence should be acknowledged. Experience with these techniques in SjD patients may improve the probability of success, given the particular challenges in this population [<a href="#rid87">87,88</a>].</p><p class="headingAnchor" id="H17175654"><span class="h4">Whitening products</span><span class="headingEndMark"> — </span>We avoid the use of home products for whitening or brightening of teeth in patients with dry mouth and salivary gland dysfunction since there may be increased risk from the acidity of some over-the-counter products designed for use in patients with normal salivary flow and content and increased risk of tooth sensitivity. The safety of these home products has not been studied in patients with SjD, although whitening strips containing 10% hydrogen peroxide were well tolerated compared with placebo in a randomized trial in subjects with medication-induced xerostomia [<a href="#rid89">89</a>].</p><p>In patients in whom professionally applied whitening processes are undertaken, the use of a remineralizing solution containing calcium phosphate and a <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> treatment may be beneficial in conjunction with a bleaching treatment. Such procedures should only be performed after consultation by the patients with their dry mouth dentist.</p><p class="headingAnchor" id="H4618155"><span class="h2">Oral candidiasis</span><span class="headingEndMark"> — </span>The treatment of oral candidiasis in SjD is similar to that of other patients with oropharyngeal candidiasis [<a href="#rid90">90</a>] but requires consideration of several SjD-related factors that influence management decisions in these patients [<a href="#rid5">5,91,92</a>]. Recognition of the clinical manifestations of chronic erythematous candidiasis, typically oral pain or burning, is the first step in effective treatment; these manifestations are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease", section on 'Oral candidiasis'</a> and  <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a>.)</p><p>The SjD-related factors and strategies include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment preferences vary among oral medicine specialists. Some prefer treatment with <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches, 10 mg 5 times daily; <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> mucoadhesive buccal 50 mg tablet, applied once daily; or <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> suspension 500,000 units 4 times daily for 7 to 14 days. These recommendations mirror guidelines of the Infectious Diseases Society of America for patients without salivary hypofunction [<a href="#rid90">90</a>]. The high sugar content of nystatin suspension and clotrimazole troches may accelerate the development of dental caries in SjD patients with severe salivary hypofunction [<a href="#rid93">93</a>]. Accordingly, the sugar-free miconazole mucoadhesive buccal tablet would be the best topical product. However, high cost and limited availability of these tablets hinder their use in clinical practice. Additionally, patients with little to no salivary flow may have difficulty dissolving the clotrimazole troches, decreasing their effectiveness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the reasons stated above, the authors prefer the use of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 100 mg tablets (2 tablets on the first day followed by 1 tablet daily for 14 to 21 days). We also recommend oral fluconazole for patients with recurrent oral candidiasis, in whom monthly courses of treatment or suppressive treatment may be necessary. For these patients, systemic treatment with fluconazole avoids exposure to the sugars in topical preparations, such as <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches or <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> suspension and enhances compliance compared with multiple daily dosing needed for the topical agents.</p><p></p><p class="bulletIndent1">An alternative approach is the once-daily use of an oral suspension of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, 10 mL of a 10 mg/mL solution. The patient rinses the mouth with the suspension for 2 to 3 minutes and then swallows it [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1">The pharmacokinetics of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> in saliva and plasma were compared in 10 healthy subjects after either swishing an oral suspension in the mouth for two minutes and then swallowing it or ingesting the same dose as a capsule [<a href="#rid95">95</a>]. The former treatment regimen resulted in significantly higher peak saliva concentrations and mean area under the concentration-versus-time curves from 0 to 24 hours. Thus, fluconazole oral suspension, swished for two minutes and then swallowed, has theoretical pharmacokinetic advantages over swallowing a tablet in the treatment of oropharyngeal candidiasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The advantages of oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> include once-daily dosing (leading to better patient adherence) and simultaneous treatment of esophageal and vaginal candidiasis, if present. (See  <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other options include <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> vaginal troches or vaginal tablets. These vaginal products do not contain sugar and can be used orally without concerns for accelerating dental caries. However, the latter are not available in the United States. An alternative approach is to prescribe troches containing 100,000 units of nystatin and flavored with artificial sweeteners from a compounding pharmacy.</p><p></p><p class="bulletIndent1">These antifungal troches and vaginal tablets should be dissolved slowly in the mouth over 15 to 20 minutes. As with <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches, the <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> vaginal troches and dissolvable tablets may not be tolerated in patients with severe salivary hypofunction due to problems with solubilizing the medication. Therefore, frequent sips of water may aid tablet dissolution; however, care must be taken as frequent rinsing may wash the product away and reduce efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with observable saliva production but lack of adequate response, we increase the dose of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> to 200 mg per day or treat with other azoles, such as <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> if the candidal species is resistant to fluconazole. (See  <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antifungal treatment should be continued for 7 to 10 days or until there is resolution of the mucosal erythema, restoration of filiform papillae on the dorsal tongue, and eradication of the oral symptoms (eg, burning, sensitivity to spicy foods, change in taste, and metallic taste). The endpoint of treatment should be relief of symptoms and resolution of the oral signs. With successful treatment, the tongue may regain its normal appearance. Treatment periods may sometimes need to be extended to three to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrences are common and will require retreatment. Patients with more than one recurrence can be treated prophylactically with repeat courses every month or <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 100 mg three times a week.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with partial or complete dentures, the topical oral antifungal treatment should be performed with the denture removed. Alternatively, if using <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> powder, it can be sprinkled onto the tissue-contact surface of the removable denture prior to placing the denture in the mouth during the day.</p><p></p><p class="bulletIndent1">The dentures can be soaked overnight in 0.2% <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> or a dilute bleach solution (1 part household bleach to 10 parts water) [<a href="#rid5">5</a>]; however, use of the dilute bleach solution should be avoided with partial dentures containing metal connectors or clasps, as they may get corroded or tarnished.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A daily probiotic was shown to reduce oral candidal load significantly when compared with placebo capsules in a 5-week study involving 32 patients with SjD [<a href="#rid96">96</a>]. The use of probiotics may thus be an alternative approach to management of recurrent oral candidiasis in this disease.</p><p></p><p class="headingAnchor" id="H24155524"><span class="h1">TREATMENT OF OTHER SICCA SYMPTOMS</span><span class="headingEndMark"> — </span>Patients should also be treated for other sicca symptoms in addition to dry eye and dry mouth; these include nasal dryness, laryngotracheal and genitourinary symptoms, and dry skin. These problems have not been the focus of randomized trials or other studies performed in patients with Sjögren’s disease (SjD), and their management is largely based upon the treatment of non-SjD patients and upon clinical experience.</p><p>Patients with these manifestations may also benefit from the use of muscarinic agonists, such as <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> or <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>. Two randomized trials of pilocarpine for dry mouth and dry eye suggested that the drug may be more effective than placebo for symptoms of nasal, skin, and vaginal dryness and for the ability to expectorate mucus [<a href="#rid38">38,42,43</a>].</p><p class="headingAnchor" id="H13441414"><span class="h2">Nasal dryness</span><span class="headingEndMark"> — </span>Treatment of nasal dryness may improve comfort and alleviate congestion that could increase mouth breathing and exacerbate oral dryness. Room humidifiers may also be helpful, and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> nasal sprays should be used as needed. Gentle nasal lavage can be used to remove encrusted secretions. Additional causes of nasal blockage, such as nasal polyps and sinus infection, should be identified and treated appropriately. (See  <a class="medical medical_review" href="/z/d/html/7535.html" rel="external">"Etiologies of nasal obstruction: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H13441422"><span class="h2">Laryngotracheal irritation</span><span class="headingEndMark"> — </span>Patients with gastroesophageal reflux disease (GERD) should be treated appropriately; such symptoms may mimic those of recurrent sinusitis, burning mouth pain, or allergy, such as postnasal drip or frequent throat clearing with mucus, due to laryngotracheal irritation, which stimulates vagal responses [<a href="#rid97">97</a>]. Inappropriate treatment with antibiotics for presumed sinusitis can increase the risk of oral candidiasis. (See  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a>.)</p><p class="headingAnchor" id="H13441430"><span class="h2">Genitourinary symptoms</span><span class="headingEndMark"> — </span>Women with SjD may experience symptoms from vaginal dryness related to SjD and/or from estrogen deficiency or an associated disorder such as interstitial cystitis. Additionally, women with SjD may be more susceptible to candida vulvovaginitis, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a> and  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H17175672"><span class="h3">Vaginal dryness and dyspareunia</span><span class="headingEndMark"> — </span>A variety of preparations are available for the treatment of vaginal dryness, including topical moisturizers and lubricants; topical vaginal estrogens and hyaluronic acid vaginal creams may benefit patients with estrogen deficiency [<a href="#rid98">98</a>]. Patients with symptomatic vaginal dryness should be evaluated and treated in collaboration with an expert in gynecologic care. There are no randomized trials comparing the various available products in patients with SjD. Patients may need to try several different products as they differ in their viscosity, and scented products should be avoided [<a href="#rid99">99,100</a>]. In patients with dyspareunia due to vaginal dryness, use of a lubricant by the patient's male partner may also be of benefit. The treatments of vaginal dryness and dyspareunia are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/5409.html" rel="external">"Female sexual pain: Differential diagnosis", section on 'Decreased lubrication'</a>.)</p><p class="headingAnchor" id="H17175680"><span class="h3">Interstitial cystitis and pelvic pain</span><span class="headingEndMark"> — </span>The treatments of vulvodynia (formerly vulvar vestibulitis) and interstitial cystitis are discussed in detail separately. These conditions may be exacerbated by dryness and candidiasis in patients with SjD. The use of tricyclic antidepressants, sometimes employed for treatment of these conditions, should be avoided in patients with SjD because of their anticholinergic side effects. (See  <a class="medical medical_review" href="/z/d/html/8085.html" rel="external">"Interstitial cystitis/bladder pain syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8087.html" rel="external">"Interstitial cystitis/bladder pain syndrome: Management"</a> and  <a class="medical medical_review" href="/z/d/html/5413.html" rel="external">"Vulvar pain of unknown cause (vulvodynia): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/110586.html" rel="external">"Vulvar pain of unknown cause (vulvodynia): Treatment"</a>.)</p><p class="headingAnchor" id="H13441470"><span class="h2">Dry skin</span><span class="headingEndMark"> — </span>Treatment of dry skin in patients with SjD is similar to the management of xerosis in other medical conditions and includes the use of mild cleansers, skin moisturizers, and/or occlusive agents; the avoidance of excessive skin washing; and the use of a humidifier. The management of xerosis and related pruritus is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Xerosis (dry skin)'</a>.)</p><p>Fragranced moisturizers and heavily fragranced cleansers should be avoided, as should use of oral antihistamines, when possible, in patients with SjD and pruritus because of their irritative and anticholinergic effects, respectively. We also advise patients with SjD, regardless of whether it is associated with systemic lupus, to use sunblock, sunscreen, and sun-protective clothing for additional skin protection. (See  <a class="medical medical_review" href="/z/d/html/6620.html" rel="external">"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection"</a>.)</p><p class="headingAnchor" id="H13441478"><span class="h2">Other symptoms</span></p><p class="bulletIndent1"><span class="glyph">●</span>Perioral paresthesia and dry, cracking perioral skin or lips may be treated with frequent use of lip salves and/or petroleum jelly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alterations in smell and taste may occur in SjD patients; they may respond to treatment of occult candidiasis or replacement of zinc deficiency [<a href="#rid101">101</a>]. Some studies and small trials in patients without SjD but with diminished taste associated with radiotherapy or other causes have also suggested that zinc supplementation might be of benefit in improving taste sensation [<a href="#rid102">102-104</a>].</p><p></p><p class="headingAnchor" id="H2272893315"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117117.html" rel="external">"Society guideline links: Sjögren's disease"</a>.)</p><p class="headingAnchor" id="H24155545"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/580.html" rel="external">"Patient education: Sjögren's disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24155552"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with Sjögren’s disease (SjD) and dry mouth should be instructed in basic measures for self-care to stimulate oral secretions and prevent oral dryness and dental caries. These include maintaining good hydration; avoiding sucrose, carbonated beverages, juices, and water with additives; regularly sipping water; drinking sugar-free liquids; using sugar-free salivary stimulants; avoiding medications that may worsen dryness; and using a humidifier. (See <a class="local">'Basic measures for all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SjD should undergo regularly scheduled preventive dental care and be cared for by a dental hygienist and dentist with experience in dry mouth care whenever possible. Oral hygiene and dental self-care should include use of dental floss after meals, <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> either as toothpaste or mouth rinse daily, and use of toothpastes specifically designed for dry mouth. Meticulous self-care, frequent visits to the dentist, and plaque control are necessary but are not always sufficient to completely prevent caries. (See <a class="local">'Basic dental care and oral hygiene'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with SjD who get inadequate benefit from mechanical or topical stimulants of salivary flow and sipping water, we suggest the use of <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a> for temporary symptomatic relief as the next step in therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Several different preparations should be tried to find which is the most helpful. (See <a class="local">'Inadequate benefit from salivary stimulation and water'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with SjD with salivary dysfunction and dry mouth who receive inadequate benefit from mechanical stimulation and <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">artificial saliva</a>, we suggest the use of a muscarinic agonist, such as <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> or <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>, as the next therapeutic option (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The usual dose of pilocarpine is 5 mg by mouth, up to four times/day, and the usual dose of cevimeline is 30 mg by mouth, up to three times/day taken approximately a half-hour before meals. The dose of medication should be increased gradually when initiating therapy to assess for ability to tolerate side effects. In many instances, it may take several weeks for patients to notice a therapeutic effect. (See <a class="local">'Inadequate response to salivary stimulation and substitutes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally do not use glucocorticoids or other systemic antiinflammatory or immunosuppressive therapies for the treatment of sicca symptoms alone, such as dry eye and mouth, although some of these agents have beneficial effects in patients with systemic and extraglandular disease and a few have shown some efficacy for sicca symptoms, including dry mouth. (See <a class="local">'Systemic antiinflammatory and immunosuppressive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with dental caries or very low salivary production should be evaluated by a dentist with expertise in dry mouth dentistry to determine if remineralizing mouth washes, special toothpastes, <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">fluoride</a> applications, or other measures are required and to direct such care. (See <a class="local">'Dental professional care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high level of suspicion for oral candidiasis should be maintained in patients with SjD, especially in patients with mouth pain, burning, increased sensitivity, diffuse or patchy mucosal erythema, or white mucosal patches. Recurrent infections are common and patients benefit from early recognition and prompt treatment. (See <a class="local">'Oral candidiasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sicca symptoms other than dry mouth may also require treatment. In addition to dry eye, these include nasal dryness, laryngotracheal and genitourinary symptoms, and dry skin. Patients with these manifestations may benefit from various topical measures, as well as from the use of muscarinic agonists such as <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> or <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>. (See  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a> and <a class="local">'Treatment of other sicca symptoms'</a> above.)</p><p></p><p class="headingAnchor" id="H1651251124"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Creamer, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol 2016; 12:456.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79:3.</a></li><li><a class="nounderline abstract_t">Sumida T, Azuma N, Moriyama M, et al. Clinical practice guideline for Sjögren's syndrome 2017. Mod Rheumatol 2018; 28:383.</a></li><li><a class="nounderline abstract_t">Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. Rheumatology (Oxford) 2017; 56:1828.</a></li><li><a class="nounderline abstract_t">Wu AJ. Optimizing dry mouth treatment for individuals with Sjögren's syndrome. Rheum Dis Clin North Am 2008; 34:1001.</a></li><li><a class="nounderline abstract_t">Plemons JM, Al-Hashimi I, Marek CL, American Dental Association Council on Scientific Affairs. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2014; 145:867.</a></li><li><a class="nounderline abstract_t">Salum FG, Medella-Junior FAC, Figueiredo MAZ, Cherubini K. Salivary hypofunction: An update on therapeutic strategies. Gerodontology 2018; 35:305.</a></li><li><a class="nounderline abstract_t">Zero DT, Brennan MT, Daniels TE, et al. Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention. J Am Dent Assoc 2016; 147:295.</a></li><li><a class="nounderline abstract_t">Mercadante V, Al Hamad A, Lodi G, et al. Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis. Oral Oncol 2017; 66:64.</a></li><li><a class="nounderline abstract_t">Furness S, Worthington HV, Bryan G, et al. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011; :CD008934.</a></li><li><a class="nounderline abstract_t">Wu AJ. Management of salivary hypofunction in Sjögren's syndrome. Curr Treat Options Rheumatol 2015; 1:255.</a></li><li><a class="nounderline abstract_t">Tan ECK, Lexomboon D, Sandborgh-Englund G, et al. Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Metaanalysis. J Am Geriatr Soc 2018; 66:76.</a></li><li><a class="nounderline abstract_t">Rugg-Gunn AJ, Maguire A, Gordon PH, et al. Comparison of erosion of dental enamel by four drinks using an intra-oral applicance. Caries Res 1998; 32:337.</a></li><li><a class="nounderline abstract_t">Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol 2005; 5:4.</a></li><li><a class="nounderline abstract_t">Mäkinen KK. Gastrointestinal Disturbances Associated with the Consumption of Sugar Alcohols with Special Consideration of Xylitol: Scientific Review and Instructions for Dentists and Other Health-Care Professionals. Int J Dent 2016; 2016:5967907.</a></li><li><a class="nounderline abstract_t">Kerr AR, Corby PM, Shah SS, et al. Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc 2010; 141:1250.</a></li><li><a class="nounderline abstract_t">Aframian DJ, Mizrahi B, Granot I, Domb AJ. Evaluation of a mucoadhesive lipid-based bioerodable tablet compared with Biotène mouthwash for dry mouth relief--a pilot study. Quintessence Int 2010; 41:e36.</a></li><li><a class="nounderline abstract_t">Papas AS, Joshi A, MacDonald SL, et al. Caries prevalence in xerostomic individuals. J Can Dent Assoc 1993; 59:171.</a></li><li><a class="nounderline abstract_t">Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2006; 2:252.</a></li><li><a class="nounderline abstract_t">Newbrun E. Current treatment modalities of oral problems of patients with Sjögren's syndrome: caries prevention. Adv Dent Res 1996; 10:29.</a></li><li><a class="nounderline abstract_t">Young DA, Featherstone JD. Caries management by risk assessment. Community Dent Oral Epidemiol 2013; 41:e53.</a></li><li class="breakAll">http://ebd.ada.org/~/media/EBD/Files/Topical_fluoride_for_caries_prevention_2013_update.ashx (Accessed on December 01, 2016).</li><li><a class="nounderline abstract_t">Rodrigues JA, Lussi A, Seemann R, Neuhaus KW. Prevention of crown and root caries in adults. Periodontol 2000 2011; 55:231.</a></li><li><a class="nounderline abstract_t">Rantanen I, Jutila K, Nicander I, et al. The effects of two sodium lauryl sulphate-containing toothpastes with and without betaine on human oral mucosa in vivo. Swed Dent J 2003; 27:31.</a></li><li><a class="nounderline abstract_t">Tredwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth. J Dent Res 2005; 84:596.</a></li><li><a class="nounderline abstract_t">Hay KD, Thomson WM. A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:271.</a></li><li><a class="nounderline abstract_t">Xin W, Leung KC, Lo EC, et al. A randomized, double-blind, placebo-controlled clinical trial of fluoride varnish in preventing dental caries of Sjögren's syndrome patients. BMC Oral Health 2016; 16:102.</a></li><li class="breakAll">https://fgdpscotland.org.uk/wp-content/uploads/2018/09/Challacombe-Scale-oral-dryness-ENG.pdf (Accessed on April 13, 2022).</li><li><a class="nounderline abstract_t">Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2017; 69:517.</a></li><li><a class="nounderline abstract_t">Vissink A, s-Gravenmade EJ, Panders AK, et al. A clinical comparison between commercially available mucin- and CMC-containing saliva substitutes. Int J Oral Surg 1983; 12:232.</a></li><li><a class="nounderline abstract_t">Vinke J, Kaper HJ, Vissink A, Sharma PK. Dry mouth: saliva substitutes which adsorb and modify existing salivary condition films improve oral lubrication. Clin Oral Investig 2020; 24:4019.</a></li><li><a class="nounderline abstract_t">van der Reijden WA, van der Kwaak H, Vissink A, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthritis Rheum 1996; 39:57.</a></li><li><a class="nounderline abstract_t">Hardt M, Witkowska HE, Webb S, et al. Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents. Anal Chem 2005; 77:4947.</a></li><li><a class="nounderline abstract_t">Alves MB, Motta AC, Messina WC, Migliari DA. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. Quintessence Int 2004; 35:392.</a></li><li><a class="nounderline abstract_t">Aagaard A, Godiksen S, Teglers PT, et al. Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study. J Oral Pathol Med 1992; 21:376.</a></li><li><a class="nounderline abstract_t">Alpöz E, Güneri P, Onder G, et al. The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study. Clin Oral Investig 2008; 12:165.</a></li><li><a class="nounderline abstract_t">Rhodus NL, Bereuter J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. J Otolaryngol 2000; 29:28.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452.</a></li><li><a class="nounderline abstract_t">Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002; 46:748.</a></li><li><a class="nounderline abstract_t">Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 2001; 101:249.</a></li><li><a class="nounderline abstract_t">Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med 2002; 162:1293.</a></li><li><a class="nounderline abstract_t">Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999; 159:174.</a></li><li><a class="nounderline abstract_t">Papas AS, Sherrer YS, Charney M, et al. Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol 2004; 10:169.</a></li><li><a class="nounderline abstract_t">Wu CH, Hsieh SC, Lee KL, et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc 2006; 105:796.</a></li><li><a class="nounderline abstract_t">Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62:1204.</a></li><li><a class="nounderline abstract_t">Leung KC, McMillan AS, Wong MC, et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol 2008; 27:429.</a></li><li><a class="nounderline abstract_t">Cevimeline (Evoxac) for dry mouth. Med Lett Drugs Ther 2000; 42:70.</a></li><li><a class="nounderline abstract_t">Maeda M, Araki M, Fujisawa T, et al. A trial of cevimeline hydrochloride (Evoxac) for patients with Sjogren's syndrome and dry mouth. Nishinihon Journal of Dermatology 2004; 66:48.</a></li><li><a class="nounderline abstract_t">Katelaris CH. Pilocarpine for dry mouth and dry eye in Sjogren's syndrome. Curr Allergy Asthma Rep 2005; 5:321.</a></li><li><a class="nounderline abstract_t">Nelson JD, Friedlaender M, Yeatts RP, et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group. Adv Exp Med Biol 1998; 438:979.</a></li><li><a class="nounderline abstract_t">Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sjögren's syndrome. Clin Rheumatol 2007; 26:1320.</a></li><li class="breakAll">Bryne AC. Muscarinic agonists in the treatment of Sjögren's syndrome. A literature review of pilocarpine and cevimeline. 2008.</li><li><a class="nounderline abstract_t">Farag AM, Holliday C, Cimmino J, et al. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation. Oral Dis 2019; 25:1937.</a></li><li><a class="nounderline abstract_t">Tanigawa T, Yamashita J, Sato T, et al. Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia. Spec Care Dentist 2015; 35:164.</a></li><li><a class="nounderline abstract_t">Price EJ, Baer AN. How to treat Sjögren's syndrome. Rheumatology (Oxford) 2021; 60:2574.</a></li><li><a class="nounderline abstract_t">Nusair S, Rubinow A. The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Semin Arthritis Rheum 1999; 28:360.</a></li><li><a class="nounderline abstract_t">Hsu CY, Hung KC, Lin MS, et al. The effect of pilocarpine on dental caries in patients with primary Sjögren's syndrome: a database prospective cohort study. Arthritis Res Ther 2019; 21:251.</a></li><li><a class="nounderline abstract_t">Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology 2005; 74:100.</a></li><li><a class="nounderline abstract_t">Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004; 138:6.</a></li><li><a class="nounderline abstract_t">Hendrickson RG, Morocco AP, Greenberg MI. Pilocarpine toxicity and the treatment of xerostomia. J Emerg Med 2004; 26:429.</a></li><li><a class="nounderline abstract_t">Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol 2017; 69:1440.</a></li><li><a class="nounderline abstract_t">Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 2022; 399:161.</a></li><li><a class="nounderline abstract_t">Rao RS, Akula R, Satyanarayana TSV, Indugu V. Recent Advances of Pacemakers in Treatment of Xerostomia: A Systematic Review. J Int Soc Prev Community Dent 2019; 9:311.</a></li><li><a class="nounderline abstract_t">Ami S, Wolff A. Implant-supported electrostimulating device to treat xerostomia: a preliminary study. Clin Implant Dent Relat Res 2010; 12:62.</a></li><li><a class="nounderline abstract_t">List T, Lundeberg T, Lundström I, et al. The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study. Acta Odontol Scand 1998; 56:95.</a></li><li><a class="nounderline abstract_t">Blom M, Kopp S, Lundeberg T. Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. Arch Otolaryngol Head Neck Surg 1999; 125:561.</a></li><li><a class="nounderline abstract_t">Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000; 6:15.</a></li><li><a class="nounderline abstract_t">Jedel E. Acupuncture in xerostomia--a systematic review. J Oral Rehabil 2005; 32:392.</a></li><li><a class="nounderline abstract_t">Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31:952.</a></li><li><a class="nounderline abstract_t">Furness S, Bryan G, McMillan R, et al. Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 2013; :CD009603.</a></li><li><a class="nounderline abstract_t">Cho JH, Chung WK, Kang W, et al. Manual acupuncture improved quality of life in cancer patients with radiation-induced xerostomia. J Altern Complement Med 2008; 14:523.</a></li><li><a class="nounderline abstract_t">Acevedo AM, Montero M, Rojas-Sanchez F, et al. Clinical evaluation of the ability of CaviStat in a mint confection to inhibit the development of dental caries in children. J Clin Dent 2008; 19:1.</a></li><li><a class="nounderline abstract_t">Hay KD, Morton RP. The efficacy of casein phosphoprotein-calcium phosphate complex (DC-CP) [Dentacal] as a mouth moistener in patients with severe xerostomia. N Z Dent J 2003; 99:46.</a></li><li><a class="nounderline abstract_t">Banting DW, Papas A, Clark DC, et al. The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology 2000; 17:67.</a></li><li><a class="nounderline abstract_t">Van der Weijden FA, Van der Sluijs E, Ciancio SG, Slot DE. Can Chemical Mouthwash Agents Achieve Plaque/Gingivitis Control? Dent Clin North Am 2015; 59:799.</a></li><li><a class="nounderline abstract_t">Leader D. Use of chlorhexidine varnish to prevent root caries may benefit some patients. J Am Dent Assoc 2013; 144:1036.</a></li><li><a class="nounderline abstract_t">Zero DT. Are sugar substitutes also anticariogenic? J Am Dent Assoc 2008; 139 Suppl:9S.</a></li><li><a class="nounderline abstract_t">Ly KA, Milgrom P, Rothen M. Xylitol, sweeteners, and dental caries. Pediatr Dent 2006; 28:154.</a></li><li><a class="nounderline abstract_t">Ly KA, Riedy CA, Milgrom P, et al. Xylitol gummy bear snacks: a school-based randomized clinical trial. BMC Oral Health 2008; 8:20.</a></li><li><a class="nounderline abstract_t">Burt BA. The use of sorbitol- and xylitol-sweetened chewing gum in caries control. J Am Dent Assoc 2006; 137:190.</a></li><li><a class="nounderline abstract_t">Söderling E. Controversies around Xylitol. Eur J Dent 2009; 3:81.</a></li><li><a class="nounderline abstract_t">Almeida D, Vianna K, Arriaga P, Moraschini V. Dental implants in Sjögren's syndrome patients: A systematic review. PLoS One 2017; 12:e0189507.</a></li><li><a class="nounderline abstract_t">Barros AWP, Sales PHDH, Carvalho AAT, et al. Is Sjogren's syndrome a risk factor/contraindication for dental implants? An umbrella review. Spec Care Dentist 2021; 41:453.</a></li><li><a class="nounderline abstract_t">Chatzistavrianou D, Shahdad S. Implant Treatment in Patients with Sjogren's Syndrome: A Review of the Literature and Two Clinical Case Reports. Eur J Prosthodont Restor Dent 2016; 24:40.</a></li><li><a class="nounderline abstract_t">Isidor F, Brøndum K, Hansen HJ, et al. Outcome of treatment with implant-retained dental prostheses in patients with Sjögren syndrome. Int J Oral Maxillofac Implants 1999; 14:736.</a></li><li><a class="nounderline abstract_t">Korfage A, Raghoebar GM, Arends S, et al. Dental Implants in Patients with Sjögren's Syndrome. Clin Implant Dent Relat Res 2016; 18:937.</a></li><li><a class="nounderline abstract_t">Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants 2009; 24 Suppl:12.</a></li><li><a class="nounderline abstract_t">Wood MR, Vermilyea SG, Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. A review of selected dental literature on evidence-based treatment planning for dental implants: report of the Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. J Prosthet Dent 2004; 92:447.</a></li><li><a class="nounderline abstract_t">Papas AS, Kugel G, Singh M, et al. Placebo-controlled clinical trial of use of 10% hydrogen peroxide whitening strips for medication-induced xerostomia. Gerontology 2009; 55:511.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Hernandez YL, Daniels TE. Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol 1989; 68:324.</a></li><li><a class="nounderline abstract_t">Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18:571.</a></li><li><a class="nounderline abstract_t">Roberts IF, Roberts GJ. Relation between medicines sweetened with sucrose and dental disease. Br Med J 1979; 2:14.</a></li><li><a class="nounderline abstract_t">Epstein JB, Gorsky M, Caldwell J. Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:671.</a></li><li><a class="nounderline abstract_t">Koks CH, Meenhorst PL, Hillebrand MJ, et al. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother 1996; 40:1935.</a></li><li><a class="nounderline abstract_t">Kamal Y, Kandil M, Eissa M, et al. Probiotics as a prophylaxis to prevent oral candidiasis in patients with Sjogren's syndrome: a double-blinded, placebo-controlled, randomized trial. Rheumatol Int 2020; 40:873.</a></li><li><a class="nounderline abstract_t">Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sjögren's syndrome. Curr Rheumatol Rep 2003; 5:297.</a></li><li><a class="nounderline abstract_t">Jokar A, Davari T, Asadi N, et al. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial. Int J Community Based Nurs Midwifery 2016; 4:69.</a></li><li><a class="nounderline abstract_t">Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sjögren's syndrome. Am J Obstet Gynecol 1994; 170:835.</a></li><li><a class="nounderline abstract_t">Bell M, Askari A, Bookman A, et al. Sjögren's syndrome: a critical review of clinical management. J Rheumatol 1999; 26:2051.</a></li><li><a class="nounderline abstract_t">Henkin RI, Talal N, Larson AL, Mattern CF. Abnormalities of taste and smell in Sjogren's syndrome. Ann Intern Med 1972; 76:375.</a></li><li><a class="nounderline abstract_t">Tang JB. General concepts of wrist biomechanics and a view from other species. J Hand Surg Eur Vol 2008; 33:519.</a></li><li><a class="nounderline abstract_t">Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998; 82:1938.</a></li><li><a class="nounderline abstract_t">Heyneman CA. Zinc deficiency and taste disorders. Ann Pharmacother 1996; 30:186.</a></li></ol></div><div id="topicVersionRevision">Topic 14923 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411907" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672775" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409370" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice guideline for Sjögren's syndrome 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28957572" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984418" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Optimizing dry mouth treatment for individuals with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25082939" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29956369" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Salivary hypofunction: An update on therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26762707" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28249650" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161442" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Interventions for the management of dry mouth: topical therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of salivary hypofunction in Sjögren's syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29071719" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9701658" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of erosion of dental enamel by four drinks using an intra-oral applicance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740617" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840639" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gastrointestinal Disturbances Associated with the Consumption of Sugar Alcohols with Special Consideration of Xylitol: Scientific Review and Instructions for Dentists and Other Health-Care Professionals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20884928" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20213013" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of a mucoadhesive lipid-based bioerodable tablet compared with Biotène mouthwash for dry mouth relief--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095845" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Caries prevalence in xerostomic individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932698" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The management of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8934920" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Current treatment modalities of oral problems of patients with Sjögren's syndrome: caries prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916678" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Caries management by risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916678" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Caries management by risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134238" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevention of crown and root caries in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704946" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effects of two sodium lauryl sulphate-containing toothpastes with and without betaine on human oral mucosa in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972585" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Drug-induced disorders of teeth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11925535" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664129" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized, double-blind, placebo-controlled clinical trial of fluoride varnish in preventing dental caries of Sjögren's syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664129" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized, double-blind, placebo-controlled clinical trial of fluoride varnish in preventing dental caries of Sjögren's syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27390247" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6418670" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A clinical comparison between commercially available mucin- and CMC-containing saliva substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32303864" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dry mouth: saliva substitutes which adsorb and modify existing salivary condition films improve oral lubrication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546739" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053308" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15130080" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1403845" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000691" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10709169" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664046" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of primary Sjögren syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920411" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726216" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of muscarinic agonists in the treatment of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038948" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9927101" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043506" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000452" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644860" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899308" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10932302" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cevimeline (Evoxac) for dry mouth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A trial of cevimeline hydrochloride (Evoxac) for patients with Sjogren's syndrome and dry mouth</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pilocarpine for dry mouth and dry eye in Sjogren's syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9634998" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17221146" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy prediction of cevimeline in patients with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17221146" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy prediction of cevimeline in patients with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31520497" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25639487" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30770917" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : How to treat Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406404" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of oral pilocarpine in xerostomia and Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31775834" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effect of pilocarpine on dental caries in patients with primary Sjögren's syndrome: a database prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15722648" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of cevimeline on salivary components in patients with Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234277" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093850" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pilocarpine toxicity and the treatment of xerostomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296257" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861168" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31516864" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recent Advances of Pacemakers in Treatment of Xerostomia: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681934" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Implant-supported electrostimulating device to treat xerostomia: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669460" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10326815" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673783" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899016" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acupuncture in xerostomia--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341529" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Systematic review of acupuncture in cancer care: a synthesis of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24006231" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Interventions for the management of dry mouth: non-pharmacological interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18532895" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Manual acupuncture improved quality of life in cancer patients with radiation-induced xerostomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18500152" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical evaluation of the ability of CaviStat in a mint confection to inhibit the development of dental caries in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332459" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The efficacy of casein phosphoprotein-calcium phosphate complex (DC-CP) [Dentacal] as a mouth moistener in patients with severe xerostomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11808057" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26427569" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Can Chemical Mouthwash Agents Achieve Plaque/Gingivitis Control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989843" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Use of chlorhexidine varnish to prevent root caries may benefit some patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18460675" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Are sugar substitutes also anticariogenic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16708791" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Xylitol, sweeteners, and dental caries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657266" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Xylitol gummy bear snacks: a school-based randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16521385" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The use of sorbitol- and xylitol-sweetened chewing gum in caries control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19421385" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Controversies around Xylitol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29240793" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dental implants in Sjögren's syndrome patients: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33987854" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Is Sjogren's syndrome a risk factor/contraindication for dental implants? An umbrella review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039478" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Implant Treatment in Patients with Sjogren's Syndrome: A Review of the Literature and Two Clinical Case Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10531746" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Outcome of treatment with implant-retained dental prostheses in patients with Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26399938" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dental Implants in Patients with Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19885432" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Systemic conditions and treatments as risks for implant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523334" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A review of selected dental literature on evidence-based treatment planning for dental implants: report of the Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707010" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Placebo-controlled clinical trial of use of 10% hydrogen peroxide whitening strips for medication-induced xerostomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2788854" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1496162" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Salivary and oral components of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/466249" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Relation between medicines sweetened with sucrose and dental disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142873" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843308" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219478" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Probiotics as a prophylaxis to prevent oral candidiasis in patients with Sjogren's syndrome: a double-blinded, placebo-controlled, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531957" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The laryngeal and esophageal manifestations of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26793732" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141212" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Gynecologic manifestations of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10493692" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Sjögren's syndrome: a critical review of clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5015912" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Abnormalities of taste and smell in Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687843" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : General concepts of wrist biomechanics and a view from other species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9587128" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8835055" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Zinc deficiency and taste disorders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
